---
title: 'Computational Drug Repurposing with Multiscale Interactomes'
date: 2024-04-23
permalink: /blog/2024/01/computational-drug-repurposing-with-multiscale-interactomes
excerpt_separator: <!--more-->
toc: true
tags:
  - drug discovery
  - bioinformatics
---

Drug repurposing offers a rapid, cost-effective route to new therapies by identifying novel uses for existing compounds. When paired with **multiscale interactome analysis**, it becomes possible to explore the complex molecular relationships between drugs, targets, pathways, and diseases at a systems level.  
<!--more-->

This workflow outlines how to construct, analyze, and exploit a heterogeneous biomedical network to identify repurposing candidates, combining graph-based learning with experimental prioritization.  

---

## **1. Building the Interactome**  

The foundation of the approach is a **heterogeneous graph** that integrates multiple layers of biological knowledge. Nodes can represent drugs, proteins, pathways, or diseases, while edges encode interactions—drug–target binding, protein–protein interactions, pathway memberships, and disease associations.  

Sources like **DrugBank** provide curated drug–protein relationships, while protein–protein interaction maps can be drawn from high-confidence databases. For disease biology, integrate experimentally validated or literature-reported links, such as host–pathogen PPIs for infectious diseases or α-synuclein interactors in Parkinson’s disease.  

---

## **2. Anchoring the Disease Context**  

Once the network is assembled, the specific disease of interest is added as a node and connected to known associated proteins or pathways. This grounding ensures that the graph captures both molecular interactions and the functional context of the disease.  

---

## **3. Learning from Network Structure**  

Graph embedding techniques transform the raw network into a form suitable for machine learning. A **Node2Vec** pre-processing step captures both local neighborhoods and broader network context. These embeddings are then refined through a **Graph Convolutional Network (GCN)**, trained with a diffusion-based loss function that clusters nodes according to their network proximity to the disease node.  

The result is a set of optimized vector representations for every entity in the network—drugs, proteins, and pathways—enabling quantitative similarity searches.  

---

## **4. Prioritizing Candidates**  

With embeddings in hand, candidate ranking is straightforward: compute cosine similarity between the disease node and other nodes. This yields:  

- **Drug proximity scores** – for direct repurposing candidates.  
- **Protein proximity scores** – highlighting potential new therapeutic targets.  

---

## **5. Multiple Selection Strategies**  

Three complementary selection approaches can be applied:  

1. **Target-centric**: Choose drugs directly most similar to the disease node.  
2. **Protein-centric**: Identify top-ranked proteins, then retrieve predicted binders from platforms like **PolypharmDB**.  
3. **Polypharmacology-focused**: Prioritize drugs predicted to act on multiple high-value targets simultaneously.  

---

## **6. Rational Filtering**  

To refine the shortlist, apply pragmatic filters: retain only FDA-approved small molecules with drug-like properties, ensure scaffold diversity, and avoid redundancy in mechanism of action or target profile.  

---

## **7. From Prediction to Validation**  

Predicted candidates move to experimental testing, starting with **cell-based assays** tailored to the disease model—such as infection inhibition assays, pseudovirus entry tests, or phenotypic screens. Hits are further confirmed with orthogonal validation techniques, from qRT-PCR to targeted inhibition assays.  

---

By uniting **network pharmacology**, **graph machine learning**, and **experimental feedback**, this interactome-driven strategy offers a scalable framework for uncovering repurposing opportunities across a broad range of diseases. Its strength lies in connecting molecular context with computational inference—transforming existing drugs into tomorrow’s targeted therapies.  
